127 related articles for article (PubMed ID: 34114996)
1. Identification of potential diagnostic biomarkers in MMPs for pancreatic carcinoma.
Xie J; Zhou X; Wang R; Zhao J; Tang J; Zhang Q; Du Y; Pang Y
Medicine (Baltimore); 2021 Jun; 100(23):e26135. PubMed ID: 34114996
[TBL] [Abstract][Full Text] [Related]
2. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential.
Gobin E; Bagwell K; Wagner J; Mysona D; Sandirasegarane S; Smith N; Bai S; Sharma A; Schleifer R; She JX
BMC Cancer; 2019 Jun; 19(1):581. PubMed ID: 31200666
[TBL] [Abstract][Full Text] [Related]
3. MMP1 and MMP9 are potential prognostic biomarkers and targets for uveal melanoma.
Wang T; Zhang Y; Bai J; Xue Y; Peng Q
BMC Cancer; 2021 Sep; 21(1):1068. PubMed ID: 34587931
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel therapeutic target and prognostic biomarker in matrix metalloproteinase gene family in pancreatic cancer.
Luan H; Jian L; Huang Y; Guo Y; Zhou L
Sci Rep; 2023 Oct; 13(1):17211. PubMed ID: 37821678
[TBL] [Abstract][Full Text] [Related]
5. Identification of the MMP family as therapeutic targets and prognostic biomarkers in the microenvironment of head and neck squamous cell carcinoma.
Liu M; Huang L; Liu Y; Yang S; Rao Y; Chen X; Nie M; Liu X
J Transl Med; 2023 Mar; 21(1):208. PubMed ID: 36941602
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study.
Pietruszewska W; Bojanowska-Poźniak K; Kobos J
Otolaryngol Pol; 2016 Jun; 70(3):32-43. PubMed ID: 27386931
[TBL] [Abstract][Full Text] [Related]
7. Landscape Analysis of Matrix Metalloproteinases Unveils Key Prognostic Markers for Patients With Breast Cancer.
Cheng T; Chen P; Chen J; Deng Y; Huang C
Front Genet; 2021; 12():809600. PubMed ID: 35069702
[TBL] [Abstract][Full Text] [Related]
8. A quantitative gene expression profile of matrix metalloproteinases (MMPS) and their inhibitors (TIMPS) in the myocardium of patients with deteriorating heart failure requiring left ventricular assist device support.
Felkin LE; Birks EJ; George R; Wong S; Khaghani A; Yacoub MH; Barton PJ
J Heart Lung Transplant; 2006 Dec; 25(12):1413-9. PubMed ID: 17178334
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of the Expression and Prognosis for MMPs in Human Colorectal Cancer.
Yu J; He Z; He X; Luo Z; Lian L; Wu B; Lan P; Chen H
Front Oncol; 2021; 11():771099. PubMed ID: 34804973
[TBL] [Abstract][Full Text] [Related]
10. Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma.
Li Y; Zhu YY; Dai GP; Wu DJ; Gao ZZ; Zhang L; Fan YH
Math Biosci Eng; 2019 Nov; 17(1):910-927. PubMed ID: 31731384
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human optic nerve head astrocytes.
Agapova OA; Ricard CS; Salvador-Silva M; Hernandez MR
Glia; 2001 Mar; 33(3):205-16. PubMed ID: 11241738
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma.
Xu L; Yang H; Yan M; Li W
Clin Exp Med; 2023 Oct; 23(6):2065-2083. PubMed ID: 36169759
[TBL] [Abstract][Full Text] [Related]
13. New signaling pathways from cancer progression modulators to mRNA expression of matrix metalloproteinases in breast cancer cells.
Delassus GS; Cho H; Eliceiri GL
J Cell Physiol; 2011 Dec; 226(12):3378-84. PubMed ID: 21344390
[TBL] [Abstract][Full Text] [Related]
14. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma.
Bramhall SR; Neoptolemos JP; Stamp GW; Lemoine NR
J Pathol; 1997 Jul; 182(3):347-55. PubMed ID: 9349239
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials.
Bloomston M; Zervos EE; Rosemurgy AS
Ann Surg Oncol; 2002 Aug; 9(7):668-74. PubMed ID: 12167581
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma.
Gu ZD; Li JY; Li M; Gu J; Shi XT; Ke Y; Chen KN
Am J Gastroenterol; 2005 Aug; 100(8):1835-43. PubMed ID: 16086722
[TBL] [Abstract][Full Text] [Related]
17. Matrix Metalloproteinases: A challenging paradigm of cancer management.
Alaseem A; Alhazzani K; Dondapati P; Alobid S; Bishayee A; Rathinavelu A
Semin Cancer Biol; 2019 Jun; 56():100-115. PubMed ID: 29155240
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase 14 and 19 expression is associated with thoracic aortic aneurysms.
Jackson V; Olsson T; Kurtovic S; Folkersen L; Paloschi V; Wågsäter D; Franco-Cereceda A; Eriksson P
J Thorac Cardiovasc Surg; 2012 Aug; 144(2):459-66. PubMed ID: 21955474
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer.
Gong YL; Xu GM; Huang WD; Chen LB
J Surg Oncol; 2000 Feb; 73(2):95-9. PubMed ID: 10694645
[TBL] [Abstract][Full Text] [Related]
20. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
